Corbus Pharmaceuticals Holdings, Inc. [NASDAQ:CRBP]: Analyst Rating and Earnings

Pro stock market traders often keep their attention pointed at what top market analysts have to say regarding a potential equity investment. For Corbus Pharmaceuticals Holdings, Inc. [CRBP] currently, the latest-available mean analyst rating is for the fiscal quarter that will end in December. On average, stock market experts give CRBP an Outperform rating. Its stock price has been found in the range of 4.50 to 9.11. This is compared to its latest closing price of $6.52.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Corbus Pharmaceuticals Holdings, Inc. [CRBP] is sitting at 2.00. This is compared to 1 month ago, when its average rating was 2.00.

Keep your eyes peeled for this company’s upcoming financial results publication, which is slated for Thu 9 May (In 56 Days).

Fundamental Analysis of Corbus Pharmaceuticals Holdings, Inc. [CRBP]

Now let’s turn to look at profitability: with a current Operating Margin for Corbus Pharmaceuticals Holdings, Inc. [CRBP] sitting at -1334.43.

This company’s Return on Total Capital is -96.74, and its Return on Invested Capital has reached -56.00%. Its Return on Equity is -97.21, and its Return on Assets is -76.41. These metrics suggest that this Corbus Pharmaceuticals Holdings, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organization’s capital structure, Corbus Pharmaceuticals Holdings, Inc. [CRBP] has generated a Total Debt to Total Equity ratio of 0.58. Similarly, its Total Debt to Total Capital is 0.58, while its Total Debt to Total Assets stands at 0.50. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 0.00, and its Long-Term Debt to Total Capital is 0.00. This company has a healthy balance between its debt and its current holdings, suggesting it is a reliable investment due to its ability to leverage debt in an efficient way.

What about valuation? This company’s Enterprise Value to EBITDA is -5.79. The Enterprise Value to Sales for this firm is now 67.54, and its Total Debt to Enterprise Value stands at 0.00. Corbus Pharmaceuticals Holdings, Inc. [CRBP] has a Price to Book Ratio of 6.83.

Shifting the focus to workforce efficiency, Corbus Pharmaceuticals Holdings, Inc. [CRBP] earns $51,919 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 3.67 and its Total Asset Turnover is 0.06. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 7.98 and its Current Ratio is 7.98. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Corbus Pharmaceuticals Holdings, Inc. [CRBP] has 63.07M shares outstanding, amounting to a total market cap of $430.77M. Its stock price has been found in the range of 4.50 to 9.11. At its current price, it has moved by -25.03% from its 52-week high, and it has moved 51.78% from its 52-week low.

This stock’s Beta value is currently 2.16, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 46.76. This RSI score is good, suggesting this stock is neither overbought or oversold.

Conclusion: Is Corbus Pharmaceuticals Holdings, Inc. [CRBP] a Reliable Buy?

Shares of Corbus Pharmaceuticals Holdings, Inc. [CRBP], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.